Curated News
By: NewsRamp Editorial Staff
April 30, 2025
Nutriband Outlines Key Achievements and Plans for 2025 with AVERSA Technology
TLDR
- Nutriband (NASDAQ: NTRB) anticipates $200M & $130M peak sales for AVERSA Fentanyl & Buprenorphine, targeting pivotal clinical trials and NDA filings.
- Nutriband is advancing AVERSA technology with Kindeva Drug Delivery, transitioning from feasibility to commercial development, raising $8.4M in non-brokered placement.
- Nutriband aims to prevent drug abuse through AVERSA technology, expanding global patent portfolio to 46 countries, expecting revenue growth from partnerships in 2025.
- Nutriband raises $8.4M, expands global patent portfolio, and collaborates with Kindeva Drug Delivery to advance AVERSA technology and prevent drug abuse.
Impact - Why it Matters
This news matters as it highlights Nutriband's progress in developing abuse-deterrent transdermal technology, which could have a significant impact on the pharmaceutical industry. Investors and stakeholders should take note of the company's advancements and potential for revenue growth in 2025.
Summary
Nutriband (NASDAQ: NTRB) has outlined key achievements in 2024 and plans for 2025, focusing on advancing its AVERSA abuse-deterrent transdermal technology in partnership with Kindeva Drug Delivery. The company expects peak annual sales of up to $200 million for AVERSA Fentanyl and $130 million for AVERSA Buprenorphine. Nutriband also raised $8.4 million in a non-brokered placement and expanded its global patent portfolio to 46 countries.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Outlines Key Achievements and Plans for 2025 with AVERSA Technology
